

IpA

IMMUNOPRECISE ANTIBODIES

FY 2025 Q2

Earnings Presentation



Disclosures

Disclaimer

This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company’s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company’s potential cash generation performance in any way.

Forward Looking Statements

This presentation includes forward-looking statements (within the meaning of applicable securities laws) to provide prospective investors with information pertaining to the Company’s long-term business objective. Forward-looking statements often, but not always, are identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeting” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, or “might” occur or be achieved and other similar expressions.

Forward-looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company’s management about the Company’s business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation.

The forward-looking statements that are contained in this presentation involve a number of risks and uncertainties and are based on certain assumptions, including but not limited to: the progress, timing and costs related to the execution of the Company’s business plan and strategy; estimates and projections regarding the industry in which the Company operates; the future success of research and development activities; the absence of material changes in general business and economic conditions; estimates regarding the future financing and capital requirements; and the absence of adverse changes in relevant laws and regulations. As a consequence, actual results might differ materially from results forecast or suggested in these forward-looking statements. Please see the Company’s most recent Annual Information Form, which is available under the Company’s profile on EDGAR at www.sec.gov/edgar and SEDAR+ at www.sedarplus.ca for additional related risks factors that could materially affect the Company’s operations and financial results.

Furthermore, forward-looking statements contained herein are made as of the date of this MD&A presentation and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise except as required by applicable securities. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.



Fiscal Year 2025 Q2 Business Update



Corporate Update

Strategic Development & Leadership

Headquarters will be relocating to Austin, Texas

Austin has rapidly emerged as a global hub for artificial intelligence and biotechnology



Corporate Update

Strategic Development & Leadership

Leadership update

Dr. Barry A. Springer,
Retiring from
IPA Board of Directors



Strategic divestitures: streamlining for growth

Two European wet labs



- Utrecht
- Oss, the Netherlands

Corporate Update

Cost Cutting Measures

Commitment to financial discipline

Executive compensation updates



Concluding relationship with Quantum IR

Focused on a responsive investor relations strategy

Corporate Update

Strategic Partnerships and Industry Engagement

AI-Driven Drug Discovery Summit Fireside Chat

Titled: “Beyond Conventional Biologics: The Intersection of Machine Learning and Biological Engineering to Invent Novel Medicines”

- Dirk Van Hyfte, BioStrand
- Adam Root, Generate Biomedicines

TECHday Highlights

“The speed of the best Google algorithms and machine learning is nothing compared to what BioStrand is able to do.”

Jeff Fried, InterSystems Head of Product Management



Corporate Update

Strategic Development

We're excited to announce our rebranding initiative

Science-powered, technology-driven, unified and amplified.
Our transformation reflects a future of limitless potential

Business update

Collaboration and clinical success highlights



TATX-112 breakthrough in ADC development



Significant milestone update:
demonstrating our ability to target and eliminate TrkB-expressing cells.

Material transfer agreement with Biotheus



Significant development:
Biotheus has been acquired by BioNTech SE, a global leader in immunotherapy.

OncoResponse clinical success update



IPA Rabbit B cell Select® discovery

- Anti-LILRB2 antibody progresses to Ph1/2 clinical trials
- Additional dual-blockade antibody progresses to IND study

Committed to growth, collaboration and clinical success

Business update

Partnership and clinical success highlights



Mayo Clinic collaboration: advancing anti-aging research



Rabbit B cell Select[®] platform used to **developed antibodies targeting neurodegenerative diseases like Parkinson's and Alzheimer's.**

Collaboration with leading semiconductor company



Aimed at enhancing the computational efficiency of our drug discovery pipelines.

Additional collaborative talks with semiconductor innovators underway



Discussions aim to explore joint advancements. This growing strong interest from global technology leaders underscores the uniqueness of our innovations in bridging AI and life sciences.

Driving innovation at the intersection of cutting-edge AI and life sciences

Business update

BioStrand commercialization highlights



Dual revenue model combines application-based pricing through portal and API access



Application based services deployed currently on-boarding early adopters.



Data management subscriptions
This subscription model is expected to generate steady, predictable recurring revenue.

AWS partnership and deployment progress




Currently in the Foundational Technical Reviews phase, expected submission December.
AWS Partner Program first offering anticipated March 2025.

Initiatives collectively provide a balanced revenue mix and a clear pathway for sustainable growth



Fiscal Year 2025 Q2 Financial Update


Quarterly Revenue




All values listed in CAD.

Focus on growth through R&D and Sales & Marketing


Research & Development



Sales & Marketing




General & Administrative



All values listed in CAD.

Net Loss of \$2.6M, equivalent to (\$0.09) per share (basic & diluted)

Net Loss





Earnings Per Share



All values listed in CAD.

Ending Q2 Cash Balance of \$3.6M



All values listed in CAD.

Q&A

FY 2025 Q2
Earnings Call



December 10, 2024 | ir.ipatherapeutics.com | NASDAQ: IPA TSXV: IPA

©2024 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidiary of ImmunoPrecise Antibodies. BioStrand, LENS[®] and HYFTS are trademarks of BioStrand, BV. Talem is an independently operating subsidiary of ImmunoPrecise Antibodies. Talem is a trademark of Talem Therapeutics LLC.

The HUB of
Biotherapeutic
Intelligence™